Trial Profile
Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123 Administered Orally to Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs CRS 3123 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions
- 04 Nov 2019 Results (n=30) assessing safety and tolerability of CRS3123 in healthy volunteers published in the Antimicrobial Agents and Chemotherapy
- 09 Jun 2016 Status changed from recruiting to completed.
- 02 Oct 2014 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 according to ClinicalTrials.gov record.